Details checkedClinical trial listing onlyHistorical/discontinuedCheckedpublication

AUT00063 by Autifony Therapeutics

Also known as: AUT00063, AUT-00063, QUIET-1, CLARITY-1, QuicKfire, AUT032063, NCT02315508, NCT02345031, NCT02832128

Autifony Therapeutics Limited

Primary source

Company

Autifony Therapeutics Limited

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Oral capsules/tablets

Confidence

86%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United Kingdom, United States

Population

adult, tinnitus, age-related, cochlear-implant

Trial IDs

Mechanism

Oral small-molecule Kv3 voltage-gated potassium-channel modulator developed to improve auditory-neuron firing and reduce central auditory hyperactivity implicated in tinnitus and hearing impairment.

Indications

Hearing Loss Age-Related Hearing Loss Tinnitus

Notes

Verified as a real Autifony Therapeutics oral small-molecule program spanning completed Phase 2 studies in subjective tinnitus, age-related hearing loss, and post-lingual unilateral cochlear implant users. The published QUIET-1 tinnitus study reported that AUT00063 was safe and well tolerated but was not effective in alleviating tinnitus symptoms. No current active development signal was confirmed in this pass, so this should be treated as a verified historical/completed program rather than an active pipeline asset.

Evidence & Sources

6 structured sources

publication

Supports: canonicalName, aliases, company, modality, mechanism, indications, stage, status...

IDs: AUT00063, QUIET-1, NCT02315508

Open

clinicaltrials

Supports: canonicalName, company, allCompanies, modality, mechanism, indications, stage, status...

IDs: NCT02315508, AUT032063, QUIET-1

Open

registry mirror

Supports: company, allCompanies, mechanism, stage, status, route, populationTags, geography...